Feasibility Study of Laser Treatment of the Crystalline Lens to Correct Presbyopia

Inclusion Criteria: * Subjects must sign and be given a copy of the written informed consent form. * Subjects must have elected to undergo lens extraction and IOL implantation to treat their ocular disorder then elect to have the LensAR laser surgery as part of the procedure. * Cataract should not exceed LOCS III Grade 2. * Subjects must have best corrected distance visual acuity of 20/40 or better in the eye to be treated . * Subjects must be ≥ 45 years and ≤ 60 years of age at time of subject eligibility visit. * Subjects must be willing and able to return for scheduled follow up examinations for 6 months after cataract surgery or up to 3 years (at 6 month intervals) if no cataract surgery is performed. * Subject must have central 7 mm of clear cornea without vascularization Exclusion Criteria: * Subjects who are pregnant, lactating, or planning to become pregnant during the course of the study. * Subjects who have undergone previous corneal or intraocular surgery in the eye to be treated. * Subjects with a history, signs or symptoms of ocular disease or atypical finding which would be contraindicated under standard of care for cataract surgery. * Diabetic or hypertensive subjects with clinical evidence of retinal pathology. * Subjects with macular degenerative pathology. * Subjects with a history of steroid-responsive rise in IOP or uncontrolled glaucoma in either eye. * Subjects with known lens/zonular instability such as, but not restricted to, Marfan's Syndrome, Pseudoexfoliation Syndrome, etc. * Subjects with corneal disease or pathology that precludes applanation of the cornea or transmission of laser wavelength or distortion of laser light. * Subjects who cannot attain ocular dilation adequate to allow laser treatment within the minimum range based on the laser procedure to be applied. * Subjects with known sensitivity to planned study concomitant medications. * Subjects using systemic medication that is known to reduce the amplitude of accommodation (such as medication for motion sickness containing hyoscine or other antimuscarinic drugs, anticholinergic drugs, anti-psychotic drugs, tricyclic antidepressants and other drugs acting on the central nervous system). * Subjects participating in any other ophthalmic drug or device clinical trial during the time of this clinical investigation.